This strategy ignores the likelihood that even within well-defined ‘Alzheimer’s disease’ populations, in which all individuals possess substantial amyloid-β and tau pathology, a large proportion of the observed cognitive decline may still be driven by alternative pathologies due to their high prevalence and potency. The gene discussed is MAPT; the disease is Alzheimer disease.